Empirical therapy advisor
Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.
Based on 515 first isolates · MED-A · Febrile UTI / pyelonephritis · 2024-10-13 → 2025-10-12
Internal medicine ANarrowest option reaching 80 % coverage, no active warning
meropenem 84 % (81 %–87 %)
Carbapenem: reserve for ESBL / critically ill patients.
Not covered: Enterococcus faecalis (10 %), Staphylococcus aureus (3 %), Staphylococcus saprophyticus (2 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
Most likely organisms for this profile
Escherichia coli
54 %
Enterococcus faecalis
10 %
Klebsiella pneumoniae
10 %
Proteus mirabilis
8 %
Pseudomonas aeruginosa
6 %
Klebsiella oxytoca
4 %
Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.